During the past 12 months, Mangalam Drugs & Organics's average Total Assets Growth Rate was -14.50% per year.
During the past 3 years, the average Total Assets Growth Rate was -4.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 3.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 8.20% per year.
During the past 13 years, Mangalam Drugs & Organics's highest 3-Year average Total Assets Growth Rate was 15.90%. The lowest was -4.50%. And the median was 10.10%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Mangalam Drugs & Organics's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Mangalam Drugs & Organics Total Assets Related Terms
Mangalam Drugs & Organics Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangalam Drugs & Organics Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Mangalam Drugs & Organics's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangalam Drugs & Organics (NSE:MANGALAM) has a Total Assets of ₹3,150 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' Total Assets too high?
Mangalam Drugs & Organics' current Total Assets is ₹3,150 Mil. Overall, Mangalam Drugs & Organics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Total Assets compare to ZTS and UTHR?
Mangalam Drugs & Organics' Total Assets of ₹3,150 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current Total Assets is ₹3,150 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹63.03, compared to a current price of ₹28.09 — trading 55.4% below its estimated fair value. The current Total Assets is ₹3,150 Mil. Mangalam Drugs & Organics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Total Assets is ₹3,150 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?
Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued.
The current stock price of ₹28.09 is trading 55.4% below its estimated GF Value™ of ₹63.03.
GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.
Key valuation signals for NSE:MANGALAM:
Total Assets: ₹3,150 Mil
GF Value™: ₹63.03 vs. price of ₹28.09 (55.4% below fair value)
No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
51GF Score
Get the complete analysis for NSE:MANGALAM
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MANGALAM has been successfully added to your 
